---
title: "The Retirement Success in Maine Podcast Ep 128: Robots, AI, and the Doctor’s Office: Could Technology Change How We Age?"
description: In this Podcast, Ryan Hodapp Discusses Technology and Aging!
image: https://blog.guidancepointllc.com/hubfs/Episode%20128.png
---

[![Guidance Point Advisors](https://blog.guidancepointllc.com/hs-fs/hubfs/GuidancePointRetirementServices%20-Apr2017/Image/logo.png?width=750&height=228&name=logo.png "download.png")](https://www.guidancepointllc.com/)

[Blog](https://blog.guidancepointllc.com/) Request a call

- [Who We Are](https://www.guidancepointllc.com/who-we-are/)
- [What We Do](https://www.guidancepointllc.com/what-we-do/)
- [Who We Work With](https://www.guidancepointllc.com/who-we-work-with/)
- [Resources](https://www.guidancepointllc.com/resources/)
- [Pricing](https://www.guidancepointllc.com/pricing/)

[(207) 358-3099](tel:+(207)%20358-3099)

- [Home](https://www.guidancepointllc.com/)
- [Who We Are](https://www.guidancepointllc.com/who-we-are/)
- [What We Do](https://www.guidancepointllc.com/what-we-do/)
- [Who We Work With](https://www.guidancepointllc.com/who-we-work-with/)
- [Pricing](https://www.guidancepointllc.com/pricing/)

[Fiduciary Focus A Blog for Retirement Plans](https://blog.guidancepointllc.com/)

Request a call

If you have any questions or comments for Guidance Point, please fill out the form below and a representative will respond to you within two business days. Guidance Point values your privacy. For more information, view our Privacy Policy.

Required fields are indicated by an asterisk (\*).

# The Ready.Set.Retire! Blog

[![Share on Facebook](https://static.hubspot.com/final/img/common/icons/social/facebook-24x24.png)](http://www.facebook.com/share.php?u=https%3A%2F%2Fblog.guidancepointllc.com%2F128%3Futm_medium%3Dsocial%26utm_source%3Dfacebook) [![Share on LinkedIn](https://static.hubspot.com/final/img/common/icons/social/linkedin-24x24.png)](http://www.linkedin.com/shareArticle?mini=true&url=https%3A%2F%2Fblog.guidancepointllc.com%2F128%3Futm_medium%3Dsocial%26utm_source%3Dlinkedin) [![Share on Twitter](https://static.hubspot.com/final/img/common/icons/social/twitter-24x24.png)](https://twitter.com/intent/tweet?original_referer=https%3A%2F%2Fblog.guidancepointllc.com%2F128%3Futm_medium%3Dsocial%26utm_source%3Dtwitter&url=https%3A%2F%2Fblog.guidancepointllc.com%2F128%3Futm_medium%3Dsocial%26utm_source%3Dtwitter&source=tweetbutton&text=The%20Retirement%20Success%20in%20Maine%20Podcast%20Ep%20128%3A%20Robots%2C%20AI%2C%20and%20the%20Doctor%E2%80%99s%20Office%3A%20Could%20Technology%20Change%20How%20We%20Age%3F)

# The Retirement Success in Maine Podcast Ep 128: Robots, AI, and the Doctor’s Office: Could Technology Change How We Age?

[Benjamin Smith, CFA](https://blog.guidancepointllc.com/author/benjamin-smith-cfa)  18 November 2026

## Executive Summary

![Episode 128](https://blog.guidancepointllc.com/hs-fs/hubfs/Episode%20128.png?width=899&height=506&name=Episode%20128.png)

What could retirement look like 10 or 20 years from now? From robots helping around the house to artificial intelligence transforming healthcare, emerging technologies could change how we experience aging.

In this episode of The Retirement Success in Maine Podcast, Ben and Curtis welcome Ryan Hodapp of American Beacon Partners to explore insights from ARK Invest's Big Ideas 2026 report. Together, they discuss how advancements in robotics, autonomous transportation, and medical technology could help retirees live healthier, more independent lives.

Join us as we explore the possibilities ahead and what these innovations could mean for the future of retirement!

## What You'll Learn In This Podcast Episode:

Introduction to the Future of Retirement and Technology \[04:53\]

Meet Ryan Hodapp and ARK Invest's Big Ideas 2026 \[10:52\]

Robotics, Automation, and Aging in Place \[19:31\]

Artificial Intelligence and the Future of Healthcare \[24:56\]

Advancements in Cancer Detection and Medical Treatments \[32:27\]

How AI Could Improve the Doctor-Patient Experience \[39:11

Autonomous Deliveries and Emerging Technologies \[42:36\]

Challenges to Widespread Technology Adoption \[46:48\]

Ryan's Definition of Retirement Success \[49:29\]

Closing Thoughts \[52:12\]

Resources:

[Watch the Episode Here!](https://www.youtube.com/channel/UCLyQ9VismjjQtMfix8kDe2A)

[Connect with Ryan!](https://www.linkedin.com/in/ryan-hodapp-cfa-caia-31b520/)<https://www.arctictoday.com/maine-shouldnt-take-a-backseat-to-alaska-in-plans-for-the-arctic/>

[Our GPA Team!](https://www.guidancepointllc.com/who-we-are)

## Listen Here:

<iframe style="border: none; min-width: min(100%, 430px); margin: 0px auto; display: block;" title="Robots, AI, and the Doctor's Office: Could Technology Change How We Age with Ryan Hodapp, CFA®, CAIA®" xml="lang" src="https://www.podbean.com/player-v2/?i=t828v-1bb567b-pb&amp;from=pb6admin&amp;square=1&amp;share=1&amp;download=1&amp;rtl=0&amp;fonts=Arial&amp;skin=1&amp;font-color=auto&amp;logo_link=episode_page&amp;btn-skin=7&amp;size=300" width="560" height="300" scrolling="no" allowfullscreen loading="lazy" data-name="pb-iframe-player" data-service="podbean"></iframe>

## Did you enjoy  The Retirement Success in Maine Podcast?

Subscribe to our podcast directly via Spotify, iTunes, or Podbean by clicking on the images below!

[![Spotify\_Logo\_CMYK\_Green](https://blog.guidancepointllc.com/hs-fs/hubfs/Spotify_Logo_CMYK_Green.png?width=190&name=Spotify_Logo_CMYK_Green.png)](https://open.spotify.com/show/5vphBSQ5dCu0jPBuQ9rM63?si=zSKLNxd4SUa4etrKWfAZ_w)

   

 

[![US\_UK\_iTunes\_Store\_Get\_Badge\_RGB\_012618](https://blog.guidancepointllc.com/hs-fs/hubfs/US_UK_iTunes_Store_Get_Badge_RGB_012618.png?width=225&name=US_UK_iTunes_Store_Get_Badge_RGB_012618.png)](https://podcasts.apple.com/us/podcast/the-retirement-success-in-maine-podcast/id1479140129)

<https://open.spotify.com/show/5vphBSQ5dCu0jPBuQ9rM63?si=FDTEzBaWQeicU08XYx9u1w> [![app download](https://d8g345wuhgd7e.cloudfront.net/site/images/badges/b600.png)](https://retirementsuccessinmaine.podbean.com/)

 

## Transcript:

Intro (00:01):

Do you struggle with what it means to be successful in your retirement? Trust us. You're not alone. Welcome to the Retirement Success in Maine podcast. Here, you'll go in depth with GuidancePoint advisors, investment consultants to hear stories about how retirees in Maine are navigating a successful retirement. Get insight into the inevitable challenges of aging and define what a successful retirement looks like.

Ben Smith (00:26):

Welcome everybody to the Retirement Success in Maine podcast. My name is Ben Smith, and joining me today is the neural network to my humanoid robot, Curtis Wister. How you doing today, Curtis?

Curtis Worcester (00:37):

I'm doing well, Ben. So it sounds like I'm doing the thinking here and you're the one doing all the chores and stuff.

Ben Smith (00:44):

Well, that's kind of the arrangement I was hoping for.

Curtis Worcester (00:47):

Sounds good. Sounds good to me.

Ben Smith (00:49):

Well, and apparently, of course, we're not probably that far away from robots doing some of those chores for both of us.

Curtis Worcester (00:55):

Yeah. Yeah. I think that's something a lot of us would probably sign up for.

Ben Smith (00:59):

And I know that's really where we wanted to go today was because every once in a while we like to step away from what retirement looks like right now and ask maybe a different question. What could retirement and aging look like 10 or 20 years from now?

Curtis Worcester (01:11):

Yeah, exactly. And I think technology is probably the root of that, but I think today we're going to take an approach that might be a little different than some of the technology conversations we've had on this show before. So again, we're not talking today about learning how to use our phones or staying connected back in the pandemic when everyone was learning how to use Zoom and FaceTime and everything, or even if your smart speaker can turn your lights on for you. But we're going to be talking about, I think, some bigger technological changes that could really alter what we're physically capable of doing and potentially how healthcare itself is delivered.

Ben Smith (01:48):

Yeah. And things like humanoid robots that could eventually perform physical tasks around our homes, which you think about that a little bit, artificial intelligence that could help researchers develop medicines faster, which I think would be really helpful for a lot of us as we're thinking about aging, but more sophisticated genetic and molecular testing that could help doctors detect disease earlier and choose treatments more precisely. And then lastly, technologies that may allow someone living hours away from a major medical center to benefit from expertise that historically would've required a long drive or maybe even trip out of state, which we know is happening a lot right now across the state of Maine. If I'm in Machias, I'm in Bethel, areas like that that are a little more remote, it is tougher to get access to high quality healthcare.

Curtis Worcester (02:34):

That's right. And I think our listeners know you and I are not the experts on everything, so we certainly want to have this conversation backed with some research today. And the research that we're using today as that backdrop comes from ARK Invest, so ARK Invest, Big Ideas 2026 report. And their latest research examines several major areas of technological change, including artificial intelligence, robotics and autonomous technology and biotechnology and what they call multi-omics.

Ben Smith (03:09):

Yeah. And so we're deliberately not going to spend our time today asking which company wins, what stock benefits or which technology represents the best investment. That is not what we want to do with this show anyways. So instead we want to take some of these big ideas and put them into the life of someone approaching or living through retirement. So what happens when climbing a ladder becomes difficult, but a robot can hail the task? What happens when the specialist you need is three hours away? Could a blood test eventually tell doctors more about disease before symptoms become obvious? Could AI help physicians identify the treatment most likely to work for an individual patient? And which of these ideas are close enough that today's retiree should actually care about them in which are still closer to science fiction?

Curtis Worcester (03:50):

Yeah, exactly, Ben. And again, like we just mentioned, this conversation is backed by research and also helping us sort through all of this today is our guest Ryan Hodapp. So Ryan is a vice president in the sales division of American Beacon Partners where he coordinates and supports national sales efforts for products and strategies marketed on behalf of ARK, again, ARK Investment Management. He has more than 25 years of financial services experience and has held research, portfolio management and analyst relations and client facing roles. Throughout his career, Ryan also holds both the CFA and the CAIA designations.

Ben Smith (04:29):

And before we welcome Ryan into that conversation, we do need to provide the following disclosure. American Beacon Partners is a compensated promoter for Arc Invest and is not a current client. Receipt of cash and non-cash compensation influences our referral prospective clients to Arc Invest. We are not providing investment advice or recommending an investment in Arc Invest products. So just want to make sure that that is covered before we go any further there.

Curtis Worcester (04:53):

Absolutely. And so with all of that said, Ryan, thank you so much for coming on the show today and welcome to the Retirement Success in Maine podcast.

Ryan Hodapp (05:03):

Hey, thanks so much for having me on guys. It's great to be here.

Ben Smith (05:05):

Yeah. Well, Ryan, I know we were able to talk a little bit a few weeks back and connect and there's a lot of fascinating things that we're really anxious and eager to dive into with you today. Before we get into the hot topics of the day, we want to just get a little bit of your background a little bit. So love, before we get into it, take us back to the beginning. How'd you originally find your way into the investment industry and what has kept you interested in it for more than 25 years?

Ryan Hodapp (05:33):

Okay. They get to know you, the history. Yeah, I've been in the business for 28 some odd years now, but as I think back to young Ryan when I first came in the business, my last couple years of undergrad at St. Louis University, I was interning at a broker dealer in St. Louis that used to be called AG Edwards. I was working at their home office. They had this managed products department and in managed products there was annuity marketing, life insurance marketing, mutual fund marketing, and then they also had a mutual fund research and due diligence team. And look, I was helping all of them stuff envelopes and send faxes to date myself, but I eventually gravitated towards working with the research team, helping them update performance numbers. And I was fortunate enough that the research team actually hired me on right away, right out of undergrad.

(06:17):

And it was just a great, great job to start in as a young guy in the investment business because I got to talk to some of the best investment minds in the world, in the country, everything from domestic equities, international equities, fixed income and alts and everything in between. So that I think formed what I became I guess today as opposed to what keeps me interested or what has kept me interested. I think the markets are just ever-changing. Just when you think you've seen it all, there's always something that comes along and sneaks up on you and it can surprise you. And then when we get into the technologies and innovations that we're talking about today, that becomes amplified. There's this constant state of change and even today things are just moving so quickly. And so just no day is like the next. I think that just keeps me engaged.

Curtis Worcester (07:06):

Yeah, that's fantastic. And again, as we read out there a little bit introducing you, Ryan, so you've held research portfolio and client-facing roles throughout your career like you just went through for us. How has that variety of roles really shaped the way you evaluate a new technology when everybody is telling you that it's going to, I'll use quotes for those watching, change the world? How does your diverse background within the industry really help you evaluate that?

Ryan Hodapp (07:34):

It's a really interesting question because as I think about it, I've had both the left brain and the right brain kind of roles, more research, asset allocation on one side, sales and client facing on the other. And I think what that's led to practically in my day job when I'm going out and talking about disruptive innovation, technology and whatnot, I think the left-sided brain of me, the research guy, really is paying attention to what's going on in the here and now. What are the facts? What is really going on in technology right now? The right brain side of me, the more creative side has to think longer term. What could these technologies look like in five to 10 years? And I think, to be honest, you have to have a certain imagination to really think through the here and now. We got the 24-hour news cycle, we got our cell phone attached to our hips, and it's so easy to get caught up in the here and now, but I think you need to have a little bit more of imagination.

(08:24):

And I think that sales and client-facing role has helped me with that longer term mindset that's not always easy to call out.

Curtis Worcester (08:31):

Yeah.

Ben Smith (08:31):

Nice. And Ryan, I know as part of that, as you just explained, that ability to translate is really important for people is they need to take something that maybe seems a little more complex and go, "What does this mean for me?" And be able to translate, which is I think the role of our show here today too is what we're trying to accomplish. Obviously, Arc Invest has this research that they push out on an annual basis called Big Ideas. Love to hear about, again, what's the idea behind this publishing of that and what made this latest 2026 report particularly interesting to you?

Ryan Hodapp (09:04):

Okay, so what is Big Ideas and then this most recent one, what's most interesting to me. So Big Ideas is this big research report that AHRQ puts out each and every year, and there's different versions of it, but the full-blown research version usually comes out at the end of January on an annual basis, and sometimes it's upwards of 150 pages. It's AHRQ's way to lay down their thoughts on everything from AI, humanoid robots, genomics, space exploration, all of those kind of things. And number one, it's meant to be an educational piece, here's our thoughts. If you want to know what ARC is thinking about these various technologies, this is it. Secondly, as I think about it is it does do a good job of bridging what I just described in terms of bridging the here and now with what ARC thinks might happen in the next five to 10 years.

(09:51):

So they actually provide a lot of their forecasts on where they think a lot of these technologies might be in this research report. What do I find most interesting in the 2026 version? I mean, there's so many different things. I mean, the multi-elements and genomics section alone I think I always enjoy talking about, and we're going to talk pretty heavily about that today. But there's also a whole section on are we in an AI bubble because that's kind of a hot topic. And the one little tidbit I think that's interesting in there, they talk about where we are in the adoption cycle for artificial intelligence and specifically people using those chatbots like ChatGPT and Grok and Claude on smartphones. It's only like 19% right now, believe it or not. So in terms of where we are in the adoption curve and for perspective, you go back to the mid - 90s, the adoption of web browsers on PCs was also only like 16%.

(10:39):

Then we had that five-year run till we got to the dot-com peak. So yes, AI is moving very quickly, but we still got a long way to go in terms of before we actually get to that full-blown saturation.

Curtis Worcester (10:52):

That's really interesting context. I appreciate that. And again, I know the last couple questions, you just helped us build a background on not only yourself, but the big ideas. So really want to dive in today really into our topic, and I think we try to start at maybe the broadest level we can. And this report this year talks a lot about technological convergence, so artificial intelligence getting better and then helping robotics, biology, diagnostics, and other technologies become better with it. So I guess the question for you, Ryan, why is that interaction between technologies potentially more important than any single breakthrough on its own?

Ryan Hodapp (11:31):

Right. Yeah, and it's a term that AHRQ does call convergence, and what they mean by that is two or more technologies feeding into each other, further driving adoption and growth. And so it's kind of the classic story that the sum of the parts are greater than any individual technology by themselves. And the lens through which Arc talks about it, they always describe it as S-curves feeding S-curves. And I'll describe what I mean by that. So think of an S-curve, the shape of an S as an adoption curve. The early flat part of the S is when the technology is first invented, and then you eventually have those early adopters, and it gets the growth of that technology off the ground. Then as the technology becomes more and more popular, people start using it more, you have that elevated part of the S, and that's where meaningful portion of the growth of the technology really starts to accelerate.

(12:17):

Then eventually the technology will go through some sort of maturation phase and the growth levels off, and that's kind of the top of the S or the top of the adoption curve. Well, let's take artificial intelligence and DNA sequencers, two completely separate technologies, but when you put them together, the two are better. AI improves the analytics of a DNA sequencer. Well, what ends up happening is each of them have their own S-curves. Now you have an S-curve feeding in another S-curve and bringing the two together, it extends that long, strong growth period that we see in the middle part of the adoption curve. And so that's why technological convergence is so important.

Ben Smith (12:55):

Nice. Interesting. Well, and I know, Ryan, what we want to do is bring these things a little bit more home and give real life examples and ask in that lens. So let's talk about retirement. So imagine I'm late 70s and I'm living in Maine, and again, a lot of us that are living in our homes, they're maybe not the best for us to age in, is that sometimes they're not one level, there's other obstacles, and I'm thinking about my parents, and here they are in their home and they got their washer and dryer in the basement, and then they live on that first floor. So to carry laundry up and down stairs over and over and over gets increasingly more difficult and maybe slightly a little more dangerous in terms of balance and things as we age. So when people hear humanoid robot, they probably think the Jetsons and they think science fiction, maybe I'm dating myself on the Jetsons, but what might these robots realistically be capable of doing in a home, and how far away are we from a robot that could provide meaningful physical assistance to an older adult?

Ryan Hodapp (14:08):

Man, you already beat me to my Jetsons joke. So Arc estimates in order to operate a humanoid robot successfully, it is like 200,000 times more complex relative to say a robotaxi. So a robotaxi is a fully autonomous vehicle with no human driver whatsoever. With the robotaxi, it just has to go forward, backwards, left, right. With a humanoid robot, you have to train the upper body, the lower body, the dexterity of the human hand, that's the really hard part, picking up a glass without shattering it, not to mention moving in human space. My basement looks different than my living room, which looks different than my garage. And so given the level of the complexity that it's going to take to train some of these humanoid robots, what we think is likely to happen is you're going to see the humanoid robots used in industrial factory use cases first, and that's probably in the zero to five years, the next five years or so, then we're going to have, to your point, the Rosie the robot in the home probably in that kind of five to 10 year window.

(15:08):

Now, there are some private robotics companies that are trying to overcome that, and what they're doing is they're literally paying people to wear cameras on their bodies right now to do simulated training for these humanoid robots. So it could be sooner than five to 10 years, but it is a very complex training exercise to really get them to work in the home.

Curtis Worcester (15:27):

Yeah. Wow. And so again, I know we're talking five, 10 years, maybe a touch longer, touch sooner, that's still not a crazy amount of time when we think about this. So I guess I want to build on Ben's example there of somebody who maybe, I know he mentioned maybe late 70s or mid - 70s, so now let's talk this person's mid - 80s. So mentally, we're still there. Physical tasks though are now starting to threaten this ability to remain independent. So I guess I'm just asking you to keep forecasting on this humanoid robotics theme, and again, changing the aging in place conversation. So I know we just talked about timeline. I guess what does that look like in terms of adoption into the house? What kinds of actual household tasks do you think are actually likely to become a kind of realistic first adoption?

Ryan Hodapp (16:16):

Sure. As I think about it and think of one of the earliest adopters of robots more on an industrial scale, it's a company like Amazon, their robots are very good at picking and placing things in boxes, not to oversimplify it. And I think that's going to be the likely scenario with humanoid robots picking up and placing things elsewhere, whatever the case may be. Use the example of maybe moving a heavy box up and down the stairs or whatever, laundry, dishes, anything I think that involves carrying something from one place to the other. I guess theoretically, and this is already probably starting to happen, automating the mowing of the lawn too, some of those outdoor chores I think are very realistic. So carrying things around the house is going to be kind of the likely first move. A less obvious story of automation, and this is kind of robotics and robotics adjacent, and this is tied to a very specific story I heard recently, actually has more to do with autonomous vehicles.

(17:10):

There's a gentleman by the name of Larry Goldberg that participates in these brainstorming sessions that Arc has every Friday. So what Arc does every Friday morning, they do kind of around the horn with all their analysts. They talk about all these technologies and they bring in a bunch of external venture capitalists and entrepreneurs to do a counterpoint. And Larry's one of these external venture capitalists that is often on the brainstorm. He is an 80-year-old gentleman and he lives in a neighborhood with people of a similar age. And he was telling this story not too long ago where you have the typical HOA meeting where the HOA meeting shows up in your calendar and nobody goes to it. No one wants to go to an HOA meeting. Well, Larry evidently gave a presentation at one of these HOA meetings about Tesla's full self-drive capability, and he said he had hundreds of people show up because that is another automating technology that can give people back their independence and their freedom.

(18:04):

Driving is another thing that can become more dangerous as you age, whether due to vision, reaction time, whatever the case may be, it's the unfortunate nature of aging. Well, if you have a vehicle that can drive you, that solves that problem. All of a sudden, if you have vision issues, you can literally press a button in your car, it'll take you to the restaurant, it'll take you to the grocery store. And so that was an automating robotics-related technology that also gives people back their independence that I hadn't even really thought of in terms of an interesting use case.

Curtis Worcester (18:34):

Yeah,

Ben Smith (18:35):

I appreciate you sharing that story, Ryan, because I think that's really important as something where, especially, and I'll point to the New England spirit a bit, is I think a lot of times people, they like to be independent and they don't like to ask for help. So I think if there's technology that allows them to not go, "Hey neighbor, I need to go to the grocery store because I ran out of X, Y, Z thing," the more that they can go, "Hey, there's a technology that helps me do this, a self-driving car, and I don't have to go rely on somebody and bother them and feel like I'm in a nuisance." And I think we just hear that a lot, that they don't want to bother people and they don't want to put burden on people unnecessarily, so that's really important. But I want to switch from the home to healthcare a bit, and one of the most interesting ideas obviously in this research isn't that AI isn't just helping us write emails or search the internet, it's increasingly being applied to biology itself.

(19:31):

Again, and maybe I'm speaking just for myself, but for somebody without a science background, love to just have you introduce the concept of multiomics and why would combining all that biological information with artificial intelligence potentially change how doctors understand disease?

Ryan Hodapp (19:49):

Sure, sure. Great question. So yeah, let's maybe start high level, and I know we're going to probably drill in a little bit deeper as we get into some of these subtopics, but let's define multi-omics first because everyone's like, "What does that mean?" So there are all these

Intro/Outro (20:02):

Different

Ryan Hodapp (20:02):

Omics, and I'll speak to a few of the more common or popular ones that people might be aware of. There is genomics, which is the study of our DNA. There's transcriptomics, which is the study of RNA, and there's proteomics, which is the study of the proteins in our body. The better we can understand how all of those various omics interact with each other inside of our body, the better position we're going to be in terms of coming up with therapies and treatments to help basically save lives and extend human lives. So that's kind of the promise. As we think about the artificial intelligence of it all, your email example, I think it's kind of funny, but everyone's looking at AI through the lens of corporate enterprise spending trends, how consumers are using AI, but we think they're vastly underestimating the impact that it's going to have on the healthcare sector writ large.

(20:48):

It is going to do everything from accelerate drug development to improve molecular diagnostics like cancer screening. So we'll talk about that in a little greater detail, but that's kind of the promise of what AI, and it's going to be that classic convergence story that I talked about at the beginning, when you pair AI up with DNA sequencers and things like that, the two technologies combined just get better and better, and it's going to improve healthcare outcomes.

Curtis Worcester (21:11):

Yeah, it's truly fascinating. And I think, as Ben mentioned a touch ago, we were trying to scenario play this and how does this really impact? So I have a very state of Maine specific scenario for you. So we're a rural state here. Say I'm somebody early 70s, whatever the age may be in retirement, we live in a small town way up in Northern Maine. You may have a primary care physician in your town or pretty close, but I think a reality for a lot of people with healthcare is there's specialists involved. So specialists could be at the other end of the state down in Portland area, or I think a real world example for a lot of us now in the state of Maine is Boston, is the closest true specialist medical center in terms of population center. So as diagnostics become more data-driven and AI becomes better at helping doctors analyze this information like we were just going through, do you think we could reach a point where maybe there's a shift of my medical information is now traveling to me, to home, to my primary care physician instead of me traveling to it?

(22:21):

And I know that's talking about data traveling here, but what would have to happen, do you think, for somebody in this kind of rural community to start benefiting from the same level of diagnostic expertise of somebody who maybe lives in a major city next to a major medical center?

Ryan Hodapp (22:37):

Yeah, I appreciate the rural Maine example. I grew up in a small town in Southern Illinois, so I can certainly relate to that.

Curtis Worcester (22:42):

Understood.

Ryan Hodapp (22:44):

It's a nuanced answer, and I think the main part of the answer is it kind of depends on what the physicians have on site. And not to oversimplify it, at the end of the day, do they have someone on hand that can actually do a blood draw? Because what's happening behind the scenes, and we may talk about this later, but molecular diagnostics is just getting better and better. Again, pairing up AI with the DNA sequencer, that's going to be a recurring theme today. As that molecular diagnostic screening gets better, it's going to help people uncover markers for disease and cancer and all that kind of stuff. So as long as that capability exists on hand, it's a matter of what the physician wants you to screen for or tells you to screen for. If you can do that simple blood draw, then you can send that off and those experts on analyzing that data, having the tools to analyze that data can do that in another location.

(23:35):

And then there's another screening methodology, it's not as fun to talk about, but you can also screen for colorectal cancer with stool samples too, and you can literally send that off via the mail. Again, it's not a fun thing to talk about, but it is the reality of life. And that's another thing where you can literally send it through the mail. So a lot of that's just a matter of what's on hand, what can you send off to the experts to analyze, and then have that data come to the physician to be conveyed to the end patient. The other thing that sort of solves for this, and this of course really became pretty big during the heart of the pandemic, would be telehealth. And I think in terms of how a patient uses telehealth, telehealth is a matter of how severe do you think your current malady is?

(24:15):

Sometimes you know how it is, you go into the physician's office and you literally just have a conversation, you tell them your symptoms, he prescribed something or he or she prescribes something. Well, a lot of times you don't even need to go in the doctor's office. If it's nothing too, too major, as long as it's something you can literally just have a conversation about, telehealth makes a lot of sense. And as much as people hate to say it, there are a lot of pathogens floating around in a doctor's office. So if you can avoid going in, if it's nothing too, too major, I would encourage people to use telehealth because you could go in there and all of a sudden you pick up something else. Telehealth can minimize some other things that you might pick up in the doctor's office as well.

Curtis Worcester (24:55):

Yeah, that's a great point.

Ben Smith (24:56):

Yeah, Ryan, I like that because essentially too, is I think what we see even nowadays anyways, it just feels like there's a lot of communication that's happening more with your primary care physician or medical professional just through a portal communication. I was just going to say, yeah, there's a portal, they can see the results, they say, well, it's not like you got to keep traveling back and forth physically in to see the doctor or the PA or something. So I think it looks like it's already happening, which is pretty good, which means we're all adapting and adopting maybe that technology even is just a step. But I'd like to maybe get a little bit more specific. You talked about colorectal cancer, but maybe even just generally around cancer like to talk because that's something that obviously virtually every family has been touched by. And obviously with the research, it just discusses molecular diagnostics becoming less expensive.

(25:48):

And then as you said, combining technology, combining more biological signals with AI. So I want to ask the question about could the future of screening move beyond simply asking, do you have cancer toward identifying disease earlier and then understanding its particular characteristics, and then helping a physician determine which treatment may be most appropriate for the individual patient?

Ryan Hodapp (26:12):

Yes, yes and yes. I want to address something you said in the middle of your comment and question, just that it's become less expensive. It's really important to understand why that's happening. AHRQ spends a lot of time in general seeking out technologies where the costs are declining such that it drives adoption. That is very true in this particular innovation, this particular technology. And it gets to the fact that the cost of DNA sequencing has fallen precipitously over the past couple decades. The original human genome project back in, I think it was 2003, it was $2.7 billion. Now you can sequence the human genome for a hundred bucks and it may be heading to 10 bucks. So when you fall down a cost curve that dramatically, it drives adoption. More labs can use it, more clinicians can use it because it's become more affordable. So that falling cost has been a very big driver for what's been going on behind the scenes.

(27:07):

Okay, so I talked repeatedly about para AI up at the sequencer, that improves molecular diagnostics. Why? Well, AI can analyze wide swaths of data in a way a human just cannot. There are 35 to 40 trillion cells inside of the human body. We are a walking data factory, and so that's why AI analyzing that wide swaths of data just improves what we've been able to do without that technology historically. So one of the newer innovations that's really come on the screen as all these analytics have gotten better, specifically molecular diagnostics and cancer screening, is something called an MRD test. It stands for minimal residual disease. What an MRD test does is once you've had cancer and you've gone through surgery or you've gone through treatment, these new MRD tests are showing the likelihood of whether or not that cancer might recur, and these new MRD tests are showing the likelihood of recurrence up to 20 months earlier than traditional screens.

(28:03):

So it's just helping people stay ahead of the game. And then the other innovation that's being developed, and it's kind of a silly term, it's called a liquid biopsy, and this is why I mentioned the importance of a blood draw, we are eventually going to get to the point where we're going to be able to screen for 40 different types of cancers with a simple blood draw. That technology historically was unavailable, but it's because now we can analyze that microscopic data in our bloodstream in a way that we could not in the past. So if when all of this sort of comes to fruition, I mean, we're going to save thousands and thousands of lives. Half the battle is just staying ahead of cancer because unfortunately, people often don't realize they have cancer until they show symptoms, and that's often stage three, stage four, what if we can head it off at a much earlier stage?

(28:49):

And that's what we're trying to accomplish here.

Curtis Worcester (28:51):

Yeah, it's truly just incredible. And I know we just kind of went through the diagnostic side. I guess I want to keep going. Let's say this patient does receive a diagnosis. So again, we all know today the frustrating reality that developing new treatment plans can take many years. I know we're talking about saving money on one side, but developing plans today costs a bit of money and involves many drug candidates and tests and stuff ultimately fails. How can artificial intelligence change the drug discovery and development process itself? So could that eventually mean more potential treatments reaching patients faster, which I know we just talked about certainly diagnosing faster or ahead of the current schedule, and really including people with diseases that maybe only affect relatively small populations too, which I think potentially could unlock some more niche discovery too.

Ryan Hodapp (29:50):

Sure, sure, sure. So AI's impact on drug discovery and all those types of things. And yes, it is going to accelerate drug development. So right now it takes about 12 to 13 years to make a... Drug. There are now AI drug development companies actually. And right now I think they're on pace to probably knock two to three years off that process. And I think if things continue at pace, it's closer to four to five years because what tends to happen in the development of a drug is there is a ton of failure rates before a drug even makes its way to phase one FDA drug trials. These AI drug development companies are helping to collapse those failure rates that historically happened before it even makes it to phase one. And that is where a lot of the cost of capital, that's where the expense of developing a drug gets very expensive.

(30:33):

And so this is going to, to your very point, it's going to bring drugs to market quicker. It's going to extend patent runways for the drug companies, and it's going to drive down costs by a factor of upwards of 4X, which I think also is going to be an accelerant because the drug companies are also in the business of making money. Historically, it's just been a very expensive endeavor and their return on their research and development has not been great. This is going to help the drug companies themselves, I think, which will also be an accelerant. You also had mentioned developing therapies for people, smaller patient groups, maybe rarer diseases, whatever the case may be. One of the technologies that is helping with that in particular is something called CRISPR gene editing. So CRISPR-Cas9 gene editing therapies. I am also not a geneticist, but I play one on TV.

(31:20):

So the way I think about CRISPR is you send an enzyme to a very specific spot on your DNA where something's broken, it clamps on and acts like a literal molecular DNA scissors. It cuts out the bad stuff and brings in a bridge to right the ship. And this is a permanent change in your DNA. But what's so exciting about it is the companies in this CRISPR space are creating outright functional cures. So speaking of one smaller patient group, a few years ago, we got the first in history FDA approval for a CRISPR treatment, and it was specifically for people with sickle cell disease or sickle cell anemia. People with sickle cell often have to go in the hospital 18 times a year on an emergency basis for blood transfusions. Not exactly a fun proposition. We've heard some of the earliest adopters of this CRISPR technology have gone four plus years without a single blood transfusion.

(32:08):

So it is completely life-altering. And so we're seeing therapies develop for rare diseases like that, like something called beta thalassemia, hereditary angioedema. You have horrific body swelling, it can close off your throat, and I could go on and on and on. So CRISPR is helping solve some of these rare diseases that have been more difficult to cure historically.

Ben Smith (32:27):

Awesome. Yeah, appreciate that update because that's pretty interesting. Ryan, just want to go from another practical thing that we're just facing today from a challenge in this state, and I'm sure others are too. I think as you have hospital systems and medical systems that are just, they're having trouble maybe financially, and then because of that, it's really difficult to attract physicians and retain physicians. There's a lot of mobility that's happening. And I think then getting access to physicians is hard, but also I think the caseload that physicians are dealing with is getting larger and larger. They have to see more and more patients because there's just less of them to be able to see people. So I'm just thinking about this again from the access and again, my doctor collecting all the testing, blood work, imaging, genetic information, they're talking to all of us individually, but wondering about the application of AI maybe from the doctor perspective of maybe eventually functioning as a kind of a second set of eyes for that physician.

(33:35):

Recognize patterns, flag something unusual, indicate that a patient should be referred to a

Intro/Outro (33:39):

Specialist

Ben Smith (33:40):

Sooner, because I could see where I'm busy and I got to get through this and I have 15 minutes to spend with you and I got the results and I just got to keep going and I'm just overwhelmed. So I want to ask about that question. But then the second part of that is where should we also draw the line between AI helping a physician make better decisions, but also maybe all of us maybe individually mistakenly thinking that AI can replace our physician if we just go into that chat bot we talk about, it's like I just put in my symptoms and then this chatbot then tells me this and I don't have to go to the doctor. So where's that line as well? So I want to cover both if you could.

Ryan Hodapp (34:20):

Yeah, there's lots to touch on there. And it's funny, if you look at how a lot of the usage with ChatGPT and Claude and a lot of these chatbots, a huge portion of it is people looking up questions about their own health. Now, for as much as I and Arc Invest are techno optimists, we do not believe AI is going to replace physicians by any stretch of the imagination. Rather, I think we think it's going to kind of supercharge them. Or to the opening part you were talking about just how overworked they are to some extent. It's just going to help improve, I think, their productivity as time progresses. It's one of those things that's not going to happen overnight by any stretch of the imagination, but I think in terms of how this is going to evolve, it's going to take what historically was a lot of unstructured data.

(35:04):

And what I mean by that is, you know how it is, historically you'd walk in your physician's office and they'd have the wall of manila folders. You would see it in every single doctor's office that you went to. Over time, that data is getting digitized. And that is critically important I think in terms of where AI is going to come in because as more and more of that data gets digitized, then you can start to apply AI over the top and start to do some pattern recognition, start to identify trends and things of that nature. It's just a matter of what those trends look like. Is the doctor all of a sudden starting to recommend something that's outside of the normal standard of care that they would've given to the patient or whatever the case may be? But it is. It's ultimately all about identifying patterns, making better recommendations, I think at the point of care.

(35:52):

And then even just getting back to the efficiency. I was thinking back to my last visit with my physician. He asked me, "Hey, can I record this conversation?" And I said, "Yes, absolutely." Then a lot of those AI tools will auto summarize the conversation we had, put it in bullet point formats, put it in their own kind of customer relationship management summary. That also gets digitized and helps with some of the trend analysis. Hey, did we even talk about that? You know how it is. You have a conversation with someone, you can't remember what the heck you talked about. This is going to lessen a lot of those unforced errors that can happen when you maybe only talk to your physician once a year. And then lastly, and this gets more to, I would say specialists, but I think this is important. There's a company called Tempus, and one of the things that Tempus does is they sequence tumors and then they throw AI over the top to ultimately help oncologists better recommend very specific therapies that are tied to people's specific cancers.

(36:48):

Because people could have one type of cancer, but their cellular makeup of their cancer could be very different from the person next to them. And so Tempus is using AI with sequencing data of tumors to help oncologists also make better recommendations. So that's specific to a specialist like an oncologist, but that is also, I think, a real world example where that productivity gets better.

Ben Smith (37:10):

Ryan, I want to touch on something you said in the middle there about even the transcription of conversations and doctors using this because again, just thinking about the last few visits I've had with my PA and going through this is, I mean, my experience has been every time they cozy up to the traveling workstation and they're in front of the keyboard and they're asking questions just from the form and they're typing things as they go, which I appreciate them having to get this data into the system and logging this to give better care. I completely understand why they have to do that. It does feel like it removes some of their presence in the room. It feels like their focus and their attention is on a data terminal and they're not looking at you and making a human connection and having a conversation and it's an interview back and forth.

(38:04):

And it feels a little bit more impersonal because of where their focus is. So I want to say, obviously even our industry on the financial planning side, that's something we want to make sure we're doing a lot is that there's a relationship and a connection happening. And the more connection that's happening, the more trust can be developed and the more willing that they're going to be able to say, yeah, I did have that symptom by the way. And yeah, I did because it might be a little embarrassing what I'm sharing with you, but this is the symptom of what I'm experiencing. And the more that they can be open and honest about things, the quicker they can come up with the correct diagnosis and help treatment and things like that. So that feels like it's a really important thing that even though it's small, I think from the grand scheme of everything we talked about today, it does feel like that's a pretty big development that's working its way through adoption today.

Ryan Hodapp (38:55):

Right. Recording the conversation as opposed to him staring at a screen typing away. He's taking you away from that personal interaction you normally have. If you just press a button, say, I'm going to record it, then it's going to summarize it. We can now just have a conversation. I don't have to sit there and be a robot.

Curtis Worcester (39:11):

Yeah. No, that's incredible. I think Ben knows this story, but recently we took my daughter to a walk-in care for ear infection. And the first thing the doctor had her iPhone in the chest pocket and just said, "I'm recording this for my transcription." And it was great. It's fantastic. I do want to keep going here, Ryan, and really talk about maybe a more, I shouldn't say more, another practical problem, a real world scenario. So my theme today is rural living apparently, again here in the state of Maine, but really everywhere. There's rural areas everywhere. Older in retirement, maybe we're an hour or so from our nearest pharmacy medical center. Driving isn't a task that maybe I can do or that I want to do weekly, daily, especially as our healthcare needs increase. So I want to talk about autonomous delivery. We have autonomous aerial and ground delivery systems that are already operating commercially in some markets.

(40:08):

So is there a believable future that you think where medications, lab materials, or just other healthcare supplies increasingly travel to the patient rather than requiring the patient or a caregiver to travel to them? And I think we even see real world, I know Amazon Pharmacy is a thing now where I know it's maybe not instant, but I guess what does that look like from your perspective?

Ryan Hodapp (40:33):

Sure. No, great question. We already talked about autonomous vehicles, just improving independence and autonomy in general. But yes, delivery drones is kind of the other solve for that, particularly when it comes to the delivery of medicines and things of that nature. It's a private company called Zipline, and they first came on the scene and what they were doing was they were using aerial drones to deliver drugs to people in remote areas in Sub-Saharan Africa. That was the test market for them. Once that became a real world success, they are now doing a pilot with Walmart in Dallas here in the United States. So it's kind of our first move to see, does this really work? Is this really feasible? And the short answer is right. I mean, you're going to have to solve for a lot of things. You got to make sure that they're high enough.

(41:16):

People aren't going to knock them out of the sky, all those kind of things, FAA approvals and whatnot. But yes, medicine can be delivered via these aerial drones, just goods, traditional retail goods. And then thirdly, just food delivery services as well. And that one's actually really interesting because if you've used a DoorDash or an Uber Eats or whatever the case may be, when they tack on all those extra fees, it can sometimes be twice the cost of the actual food. This is also going to help drive down those delivery costs, I think, in a very meaningful way. So aerial drones are going to solve for a lot of that. Rolling drones may be somewhere in between. That may vary from location to location because it's another one those technologies. Unfortunately, with every new technology, there's going to be bad actors. You see people knocking them over, whatever the case may be.

Curtis Worcester (42:02):

Especially with medication.

Ryan Hodapp (42:04):

Yeah, exactly. Exactly. Where we're seeing the rolling drones actually be used the most of all things is college campuses. So my son's going to Loyola Marymount in Los Angeles and they're all over campus and same kind of thing. They're bringing the kids groceries, but it's kind of a smaller hall. I have seen some in the streets of Los Angeles as well, so they're slowly starting to make it their way in major urban areas. But I think for particularly in more remote areas, the aerial drones in particular make a lot more sense.

Ben Smith (42:36):

So Ryan, I'm just envisioning right now. The drone delivers the drug or the groceries, pops it down. The humanoid robot walks out of the home, picks it up, goes up the stairs, puts it on the table, puts piece by piece away. I'm just seeing the future right now. Yeah, exactly. But I want to ask just one last technology question of you. And again, there's a temptation in everything we're talking about that we assume, because it's technically possible, it's just going to quickly just assimilate into our everyday life. And I'll pick on healthcare especially, but healthcare has regulation, it's got privacy concerns, there's insurance systems, there's infrastructure limitations, there's physician adoption, there's cost concerns. There's a Rubik's cube of problems that need to be all solved to get all the colors on the right quadrants there. So when you look at AI-assisted medicine, advanced diagnostics, human robotics, what are the biggest barriers between obviously what we're talking about this impressive demonstration today and just something that any of us could use on all these kind of topics today?

(43:48):

What are those barriers that you'd be seeing?

Ryan Hodapp (43:51):

I think you listed a lot of them and maybe I'll take each of them in turn. So the very first one you mentioned I noticed was regulation. Regulation is always, I mean, for lack of a better word, it's an air quotes risk for almost any technology. What are the politicians going to do? How are they thinking about it? AI is a political hot button issue in general right now, whether it's the build out of the data centers or there's been just concerns around safety in general. And I think what we hope happens there is safety obviously is of the utmost importance. We hope there's balance in the regulation of AI, just broadly speaking in that, yes, let's make sure that we take care of safety that should obviously be done, but let's make sure the regulation is not so onerous that the politicians fail to realize that AI is going to help us save millions of lives with what's happening in healthcare, not to mention autonomous vehicles.

(44:41):

I mean, autonomous vehicles are eight to 10 times safer than a human-driven car because we're distracted by our cell phones. So we hope there's a good middle ground with the regulation of AI, I think in general. Privacy concerns, not only healthcare, drones would be another one, right? We got to make sure that that's covered, that they're flying at a certain level, they're not using some sort of camera. I know that's going to come up. With insurance, that is obviously very healthcare specific. CRISPR is actually where that has come up the most. That sickle cell treatment that I mentioned, it costs $2 million. It is a $2 million treatment. Believe it or not, the insurance companies are paying it because when you think about it, when someone has to go in the hospital 18 times a year on an emergency basis, the cost to the healthcare system will rack up very quickly.

(45:29):

And so thus far, they've been willing to pay it because as much hate say it, health insurance companies are sort of self-serving, but at least they are paying for it, which I think is very good. And then infrastructure limitations I think was one of the last ones we mentioned. One of the other technologies we haven't really talked about that I think this applies to, it's something called EVTOL, electric vertical takeoff and landing. So we are also going to have the Jetsons air taxi coming here. So imagine if we're eventually going to get to the point where, let's say you're in downtown Manhattan or downtown Boston or whatever the case may be, and you want to jump over traffic and get to the airport, this is going to allow for that. However, similar to drones, you're going to have to solve for FAA approvals and whatnot.

(46:12):

But on the infrastructure side, you got to bill out helipads or whatever the case may be. Supposedly the coming out party for these EVTOLs is, I think it's a company called Archer Aviation. They're going to air drop the athletes into the arenas during the Olympics in Los Angeles. Well, Archer outright bought their own airport, so there's going to be some capital spending to build out the infrastructure of these EVTOLs to make it a reality. So that was kind of a wide swath, but all those things, regulation, infrastructure bill, privacy, those are all really hot button issues. They just all impact these technologies I think in different ways.

Curtis Worcester (46:48):

Yeah, no, it's fantastic. And of course, while you were just talking about that last technology there, I couldn't help but think of the recent display from Tesla with the jumping car and flipping car and stuff. So no, it's incredible to see. I think we'd echo, and a lot of our listeners would echo, just hopefully there's a balance in the regulation and adoption because I think the good will truly be impactful. So Ryan, of course, we do have one last question for you, but of course, thank you so much for coming on today and really sharing your expertise with us. I do have that last question for you, so it's a little shifted back towards you now. And I think you're a really great person to ask this question because you obviously have the financial lens, but now you're certainly into technology and healthcare and mobility, independence.

(47:35):

You're kind of covering everything here that we think about when we think about retirement. So naturally with the name of our show being Retirement Success, I have to ask you, what does retirement success look like for you? How do you think you're going to find your own retirement success?

Ryan Hodapp (47:51):

What does retirement success look for Ryan? I guess I think about that in two ways. First of all, almost through the investing lens, so maybe I'll start with my left brain first. I'm a guy that tends to practice what I preach. And what I mean by that is I do personally have investments in these various innovations and technologies, but I also know that this space, when you invest in technology, it can be volatile. There is risk to it. And so I keep the position size in my portfolio relatively modest, and then I build a whole bunch of other assets, large cap, international, et cetera. I practice what I preach. Yes, invest in innovation, but be mindful of how big your position is because it can be volatile and risky. So that's number one. And then personally, man, I'm just excited about when I think about retirement several years down the road, these technologies are going to help me.

(48:42):

I mean, I was literally having the conversation with my wife last week, that example I gave where as I get older, I can just have a car drive me to the restaurant. It can take me back home. That is super exciting. So as I think 10 years and beyond, we're kind of doing the what's happening now versus what might be coming, but even longer term, I think these technologies are really going to scale in a meaningful way. They're going to actually become pretty common, and that is exciting. And there's so much doom and gloom right now. There's kind of this AI doomerism. It's nothing but bad news when you turn on the news. I choose to take the other side of it. I am a techno optimist because I think a lot of these technologies over the long term, it's going to be for the greater good.

(49:26):

It's going to help us, it's going to help me. So that's how I think about it.

Curtis Worcester (49:29):

I love that.

Ben Smith (49:30):

Yeah, Ryan, really appreciate that because again, I join you there as I think there's so much to be optimistic about, and I think there's things that just you go, everyday annoyances or things that you just go, "Hey, we're driving to Boston and it takes a few hours to get there." It's like, "Man, wouldn't it be so much better if I could just sit in the backseat and actually get some things done or talk to your loved ones or something like that versus having to be behind the wheel and just being eyes glued to the road." So many things there that I think are going to be so beneficial. So we really appreciate you coming on the show and sharing your vantage points, sharing your optimism, and again, just giving all of us something to think about from our show today. So really appreciate you coming on and we'll hope to have you another time.

Ryan Hodapp (50:15):

Again, thanks so much for having me. This was a great conversation. I truly appreciate it.

Ben Smith (50:19):

All right, Ryan. Take

Curtis Worcester (50:20):

Care.

Ryan Hodapp (50:21):

Thanks, Ryan.

Ben Smith (50:21):

Thank you. So really great to have Ryan Hodapp on the show today. Again, I know representing American Beacon Investments, but on behalf of Arc Invest. But again, I think there's a lot of this when you're having coffee with a friend and you talk about the future and well, wouldn't it be nice if this or couldn't this happen to get a little of, no, there's some dreaming, but there's some real stuff that's coming pretty quick and just be able to think about that, of how it's going to impact our lives and think about aging, which again, I think what we value as Mainers and New Englanders is, hey, we want to stay in our house as long as possible. We like being where we are. If we're on the ocean or we're rural somewhere, we're in the mountains, we want to stay there. This is where we grew up, this is where we live, this is where we love to be.

(51:10):

These are our neighbors. We don't want to go somewhere else. And I think that's what I think hopefully you all got from this show today is there's a little bit more light on keeping us in those positions as long as possible. And it might be a little bit different than we all thought, but some really good stuff. So for all you listening out there, if you want to discover a little bit more about Arc Invest and that Big Ideas presentation, we'll have that in the show notes. If you go to blog.guidancepointllc.com/128, because we're episode 128, you can find all that there, but we really appreciate you tuning in. We appreciate the listenership. Again, I know it's been a little bit since we've posted, which is good. We've been busy with a lot of families and client stuff and talking to helping people on their daily lives, but good to get back to it with you all today and appreciate you tuning in together.

Outro (52:12):

Ladies and gentlemen, you've just listened to an information filled episode of the Retirement Success in Maine podcast. While this show is about finding more ways to improve your retirement happiness, Guidance Point Advisor's mission is to help our clients create a fulfilling retirement. We do financial planning so that people can enjoy retirement and align their monetary resources to their goals. If you are wondering about your own personal success, we invite you to reach out to us to schedule a 45-minute listening session. Our advisors will have a conversation with you about your goals, your frustrations, and your problems. Make sure you check out GuidancePoint Advisors on our blog, Facebook, and LinkedIn, and you can always check out more episodes of this podcast on iTunes and Spotify. And of course, keep on finding your retirement success.

 Topics: [Pre-Retirement](https://blog.guidancepointllc.com/topic/pre-retirement), [In Retirement](https://blog.guidancepointllc.com/topic/in-retirement), [Podcast](https://blog.guidancepointllc.com/topic/podcast)

### Subscribe to Email Updates

### Posts by Topic

- [In Retirement (144)](https://blog.guidancepointllc.com/topic/in-retirement)
- [Pre-Retirement (131)](https://blog.guidancepointllc.com/topic/pre-retirement)
- [Podcast (126)](https://blog.guidancepointllc.com/topic/podcast)
- [Business Owners & Executives (19)](https://blog.guidancepointllc.com/topic/business-owners-executives)
- [Families & Individual Investors (19)](https://blog.guidancepointllc.com/topic/families-individual-investors)
- [Saving For Retirement (19)](https://blog.guidancepointllc.com/topic/saving-for-retirement)
- [Young Professionals (18)](https://blog.guidancepointllc.com/topic/young-professionals)
- [Healthcare Professionals (4)](https://blog.guidancepointllc.com/topic/healthcare-professionals)
- [Saving for College (2)](https://blog.guidancepointllc.com/topic/saving-for-college)
- [Corporations (1)](https://blog.guidancepointllc.com/topic/corporations)
- [healthcare (1)](https://blog.guidancepointllc.com/topic/healthcare)
- [investments (1)](https://blog.guidancepointllc.com/topic/investments)

see all

- [Who We Are](https://www.guidancepointllc.com/who-we-are/)
- [What We Do](https://www.guidancepointllc.com/what-we-do/)
- [Who We Work With](https://www.guidancepointllc.com/who-we-work-with/)
- [Resources](https://www.guidancepointllc.com/resources/)
- [Pricing](https://www.guidancepointllc.com/pricing/)

[The Ready.Set.Retire! Blog](https://blog.guidancepointllc.com/) [![Guidance Point Advisors](https://blog.guidancepointllc.com/hubfs/GuidancePointRetirementServices%20-Apr2017/Image/footer%20logo.png)](https://www.guidancepointllc.com/) [(617) 869-6653](tel:+(617)%20869-6653)

Copyright © 2017 Guidance Point Advisors, LLC, all rights reserved.  
[Disclosure Statement](https://www.guidancepointllc.com/disclosure)